摘要
目的:观察芪苈强心胶囊联合西药对行经皮冠状动脉介入治疗(PCI)的急性心肌梗死(AMI)患者心肌灌注及心功能的影响。方法:选取80例行PCI治疗的AMI患者,按随机数字表法分为观察组和对照组,每组40例。对照组给予西药治疗,观察组在对照组基础上给予芪苈强心胶囊治疗,2组均治疗3个月。比较2组临床疗效及不良反应发生率,比较2组治疗前后中医证候积分、心肌梗死溶栓(TIMI)血流分级、心功能指标及血清载脂蛋白CⅢ(ApoCⅢ)、基质金属蛋白酶-9 (MMP-9)、糖类抗原125 (CA125)水平。结果:观察组总有效率为92.50%,高于对照组的70.00%(P<0.05)。治疗后,2组中医证候积分均较治疗前降低(P<0.05),观察组中医证候积分低于对照组(P<0.05)。观察组TIMI血流分级优于对照组(P<0.05);观察组TIMI 3级血流获得率为62.50%,高于对照组的37.50%(P<0.05)。治疗后,2组左室射血分数(LVEF)、心输出量(CO)、心脏指数(CI)及每搏输出量(SV)均较治疗前升高(P<0.05),左心室收缩末期内径(LVESD)、左心室舒张末期直径(LVEDD)均较治疗前缩小(P<0.05);观察组LVEF、CO、CI及SV均高于对照组(P<0.05),LVESD、LVEDD均小于对照组(P<0.05)。治疗后,2组血清ApoCⅢ、MMP-9、CA125水平均较治疗前降低(P<0.05),观察组血清ApoCⅢ、MMP-9、CA125水平均低于对照组(P<0.05)。观察组不良反应发生率为10.00%,对照组不良反应发生率为20.00%,2组比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合西药可改善AMI患者PCI术后的临床症状、心肌灌注情况及心功能,降低血清ApoCⅢ、MMP-9、CA125表达,且安全性好。
Objective: To observe the effect of Qili Qiangxin capsules combined with western medicine on myocardial perfusion and heart function of patients with acute myocardial infarction(AMI) after percutaneous coronary intervention(PCI).Methods:A total of 80 cases of AMI patients undergoing PCI were selected and divided into the observation group and the control group according to the random number table method,40 cases in each group. The control group was treated with western medicine,and the observation group was additionally treated with Qili Qiangxin capsules based on the treatment of the control group. Both groups were treated for three months. Clinical effects and incidences of adverse reactions in the two groups were compared. Chinese medicine syndrome scores,TIMI blood flow classification,heart function indexes as well as apolipoprotein CⅢ(ApoCⅢ),matrix metalloproteinase-9(MMP-9) and carbohydrate antigen 125(CA125) in serum in the two groups were compared before and after treatment. Results:The total effective rate was 92.50% in the observation group,higher than that of 70.00% in the control group(P<0.05). After treatment,Chinese medicine syndrome scores in the two groups were decreased when compared with those before treatment(P<0.05),and the score in the observation group was lower than that in the control group(P<0.05). TIMI blood flow classification in the observation group was better than that in the control group(P<0.05);The blood flow acquisition rate of grade 3 TIMI was 62.50% in the observation group,higher than that of 37.50% in the control group(P<0.05). After treatment,left ventricular ejection fraction(LVEF),cardiac output(CO),cardiac index(CI) and stroke volume(SV) in the two groups were increased when compared with those before treatment(P<0.05),and left ventricular end systolic diameter(LVESD) and left ventricular end diastolic diameter(LVEDD) were decreased(P<0.05);LVEF,CO,CI and SV in the observation group were higher than those in the control group(P<0.05),and LVESD and LVEDD were shorter(P<0.05). After treatment,the levels of ApoCⅢ,MMP-9 and CA125 in serum in the two groups were decreased when compared with those before treatment(P<0.05),and the above levels in the observation group were lower than those in the control group(P<0.05). The incidence of adverse reactions was 10.00% in the observation group and20.00% in the control group,there being no significant difference between the two groups(P>0.05). Conclusion:Based on western medicine treatment,the additional application of Qili Qiangxin capsules for patients with AMI after PCI can improve their clinical symptoms,myocardial perfusion and heart function,and reduce expressions of ApoCⅢ,MMP-9 and CA125 in serum with good safety.
出处
《新中医》
CAS
2021年第20期40-44,共5页
New Chinese Medicine
作者简介
何传玉(1990-),男,主治医师,E-mail:hechuanyu5623@163.com。
